arrow
V

Vicky Makker

Memorial Sloan Kettering Cancer Center
H指数:45
被引数:8,692

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study

极低碳水化合物生酮饮食在初治未接受过治疗的子宫内膜癌伴超重女性中的随机可行性研究

2026-05-270
OAAI
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses

曲妥珠单抗德鲁替康在DESTINY-PanTumor02研究中对HER2表达妇科癌症的抗肿瘤活性、安全性和探索性生物标志物分析

2026-05-010
PRE
Erratum to ‘Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101651]

勘误:‘实质淋巴血管间隙浸润对手术I期子宫内膜样子宫内膜腺癌首次疾病复发位置的影响’[国际妇科肿瘤杂志 卷35 期4 (2025) 101651]

2025-06-060
PRE
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors

一项随机研究,评估E7386联合仑伐替尼相较于医师选择治疗方案,在既往接受过铂类化疗和免疫检查点抑制剂治疗的晚期/复发性子宫内膜癌患者中的最佳剂量、有效性和安全性。

2025-04-050
PREAI
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate

晚期卵巢癌患者接受抗FOLR1抗体药物偶联物治疗后的临床结局

2025-04-010
PRE
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

研究总结: 通过招募HER2 IHC状态: DESTINY-PanTumor02的事后分析,曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

2025-03-010
OAAI
Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma

显著淋巴血管间隙浸润对手术期Ⅰ期子宫内膜样子宫内膜腺癌首次疾病复发部位的影响

2025-01-011
PRE
Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary

口服孕激素拮抗剂onapristone extended-release联合anastrozole治疗孕激素受体阳性的复发性成年型卵巢颗粒细胞瘤的篮子研究

2025-01-010
PRE
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

通过纳入HER2 IHC状态: DESTINY-PanTumor02的事后分析,曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

2024-09-111
OAAI
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
2024-04-234
OAAI
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
2024-01-193
OAAI
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer

研究309中的东亚亚组分析/主旨775: 来伐替尼联合帕博利珠单抗与医生选择化疗治疗晚期或复发性子宫内膜癌患者的比较

2024-01-016
OAAI
Pathogenic germline variants in patients with endometrial cancer of diverse ancestry
CANCER
IF5.1
2023-10-276
PRE
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice

Lenvatinib联合Pembrolizumab治疗或医生选择治疗的晚期子宫内膜癌患者的健康相关生活质量

2023-06-015
OAAI